U.S. FDA Accepts for Priority Review the Supplemental : vima

Media Release COPENHAGEN, Denmark; February 27, 2024 FDA grants Priority Review with target action date of June 28, 2024Application based on results from...

Related Keywords

Denmark , Japan , Valby , Hovedstaden , Tokyo , Copenhagen , Køavn , Canada , New Jersey , United States , Netherlands , American , Hematol Hemoter , Andrew Carlsen , David Freundel , Abbvie Biotechnology Ltd , Exchange Commission , Drug Administration , Data From The Observational National Lymphocare Study , Global Communications Corporate Affairs , Twitter , Exposition Of The American Society Hematology , Lymphoma Research Foundation , Priority Review , Biologics License Application , Prescription Drug User Fee Act , Chief Executive Officer , Annual Meeting , American Society , Breakthrough Therapy Designation , Follicular Lymphoma , Senior Director , Global Communications , Vice President , Media Release , Annual Report , Y Shaped Genmab , Abbvie Biotechnology , Opin Med , Bras Hematol , Subsequent Therapy , Data From , Observational National Lymphocare , Treatment Patterns , Patients With Diffuse Largeb Cell Lymphoma , Relapsed Follicular Lymphoma , Marginal Zone Lymphoma , Jacobsens Vej , Copenhagen Stock Exchange Gen , Genmaba S ,